Optical Readouts of NADPH and the NADP(H) Redox System: Recognition, Transduction, Validation, and Biological Interpretation

Abstract

Reduced nicotinamide adenine dinucleotide phosphate (NADPH) sustains reductive biosynthesis, antioxidant defense, oxidase activity, and redox signaling; nevertheless, studies framed as “NADPH imaging” often interrogate biochemically non-equivalent variables and analytically distinct endpoints. To resolve that ambiguity, this review organizes current methods by analyte-defining event, optical transduction or readout, acquisition modality, and deployment context. Extraction and enzyme-coupled assays can define recovered NADPH, oxidized nicotinamide adenine dinucleotide phosphate (NADP⁺), total NADP(H), or a derived ratio, albeit at the cost of subcellular information. By contrast, protein-based, genetically encoded, and chemigenetic systems enable reversible, compartment-addressable measurements of sensor-accessible cofactor binding, ligand-dependent assembly, relay output, or NADPH/NADP⁺ balance; however, quantitative interpretation remains contingent on affinity, sensor abundance, pH, maturation, calibration, and sensor-induced buffering. Reaction-based probes offer the broadest spectral and imaging flexibility—including ratiometric, near-infrared, two-photon, and photoacoustic formats—yet most rely on hydride-transfer chemistry shared by reduced nicotinamide adenine dinucleotide (NADH) and NADPH. Absent matched kinetics and simultaneous mixed-cofactor experiments, NAD(P)H-responsive remains the most defensible designation for these platforms. Label-free autofluorescence, fluorescence lifetime imaging microscopy (FLIM), and phasor analysis preserve native spatial context; even so, they report composite intensity, binding-state, or metabolic contrast rather than a universal absolute NADPH concentration. Across modalities, rigorous interpretation requires physiologically relevant concentration ranges, product or binding-mechanism verification, matrix- and organelle-specific controls, time-resolved calibration, and orthogonal measurements of pool size or flux. By aligning each signal-generating event with the endpoint it can legitimately support, the review establishes a mechanistic basis for platform selection and for interpreting NADPH-related optical changes across purified systems, cells, tissues, and biofluids.

1. Introduction

Reduced nicotinamide adenine dinucleotide phosphate (NADPH), a compartmentalized redox cofactor, supplies reducing equivalents for reductive biosynthesis [1,2,3]. Beyond biosynthesis, NADPH sustains antioxidant defense and broader redox homeostasis [1,4,5]. In innate immunity, the same reducing currency powers NADPH oxidases and associated redox-signaling systems [6,7]. Collectively, these functions couple redox homeostasis to intermediary metabolism and stress adaptation [8,9,10,11]. More broadly, context-specific signaling and metabolic control shape the surrounding redox network [10,11,12]. Despite this biological reach, analytical interpretation remains far from straightforward. The first challenge concerns definition: the term “NADPH signal” often collapses biochemically non-equivalent quantities into a single label. NAD(P)H denotes unresolved optical contributions from reduced nicotinamide adenine dinucleotide (NADH) and NADPH, whereas NADP(H) denotes the phosphorylated NADP⁺/NADPH couple or pool [1,4,13]. Accordingly, free NADPH, free NADP⁺, the NADPH/NADP⁺ concentration ratio, relay output, thermodynamic redox potential, and total extracted NADP(H) must be treated as analytically distinct endpoints [14,15,16].

Rather than forming a single freely equilibrating cellular pool, NADPH metabolism was described as compartmentalized, with cytosolic and mitochondrial fluxes under largely independent regulation (Figure 1). Local enzymes and transport processes further constrained additional subcellular pools [2,17]. Although bulk extraction can quantify a recovered pool, it cannot reveal the compartment from which a change originated [16,17]. Protein-defined sensors, redox relays, and binding-sensitive optical methods restore spatial resolution; nevertheless, affinity, expression, equilibrium, and calibration continue to condition their outputs [14,15,18,19].

Figure 1. Central role of the NADPH/NADP⁺ redox cycle in biological processes. The scheme summarizes major cytosolic and mitochondrial routes of NADPH generation and consumption in reductive biosynthesis, glutathione-dependent antioxidant defense, NADPH oxidase activity, and mitochondrial reactive oxygen species clearance.

Even after endpoint identity and compartment have been specified, a second—and chemically more fundamental—challenge remains: molecular discrimination. The difficulty arises because NADH and NADPH share the same reduced nicotinamide hydride donor, differing principally in the 2′-phosphate on the adenosine ribose [4,13]. Because their endogenous fluorescence overlaps extensively, conventional intensity measurements warrant the broader NAD(P)H designation unless an independently validated model supports a narrower assignment [20,21,22]. Nor do many reaction-based probes escape this limitation: electron-deficient acceptors commonly respond to the shared nicotinamide chemistry rather than directly recognizing the phosphate-bearing region of NADPH [23,24,25,26].

Accordingly, current optical platforms interrogate distinct proximal events rather than a common “NADPH signal.” Label-free fluorescence and lifetime imaging yield endogenous NAD(P)H-associated intensity or binding-state contrast [20,22,27]. By comparison, extraction and enzyme-coupled assays can quantify NADPH, NADP⁺, total NADP(H), or a derived ratio, depending on recovery and coupling design [16]. Genetically encoded systems instead resolve free-cofactor binding, ligand-dependent assembly, relay-defined responses, or reversible NADPH/NADP⁺ ratios [14,15,18,19]. Chemigenetic systems extend this protein-defined strategy, although they impose distinct assembly and labeling requirements [28]. At the opposite mechanistic extreme, reaction-based small molecules integrate chemical conversion over a defined exposure interval [24,25,29].

The review evaluates these approaches across four descriptive dimensions—the analyte-defining event, optical transduction or readout, acquisition modality, and deployment context—while treating validation as a separate layer that determines which quantitative or biological interpretation the evidence can support. Within this framework, the analyte-defining event constrains endpoint identity; Förster resonance energy transfer (FRET) describes an excited-state energy-transfer mechanism, whereas intensity, ratiometry, anisotropy, lifetime, and phasor metrics describe observable optical readouts; fluorescence lifetime imaging microscopy (FLIM), two-photon excitation, and photoacoustic detection specify acquisition modalities [18,20,22]. By contrast, mitochondrial targeting, tissue imaging, biofluid analysis, and microdroplet screening specify deployment rather than molecular selectivity [30,31,32,33]. Preserving these distinctions prevents spectral sophistication, application context, or validation burden from masquerading as chemical specificity.

Consequently, the scope extends well beyond platforms marketed as “NADPH sensors.” It encompasses measurements of sensor-accessible NADPH or NADP⁺, concentration-ratio and relay-defined NADP(H) responses, total extracted pools, and unresolved NAD(P)H-associated signals. The article follows the same inferential sequence as the framework itself: Section 2 defines the reportable endpoint and the mapping rules; Section 3 isolates the analyte-defining event; Section 4 separates optical transduction from acquisition; Section 5 introduces measurement-context constraints; Section 6 tests the resulting interpretation through validation and benchmarking; and Section 7 asks which biological conclusions survive that chain of evidence. This organization is neither a historical survey nor a ranking of technologies. Rather, it prevents a sophisticated spectrum, an attractive image, or a successful application from being mistaken for stronger molecular specificity than the underlying mechanism and controls can support. Section 7, “Biological Interpretation: Claims Supported by Current Evidence,” therefore serves as the bridge from analytical classification and validation to biological interpretation, asking how analytically defined NADPH-related endpoints can be connected to representative physiological and disease contexts and which claims are supported by the measured endpoint, perturbation design, and orthogonal controls.

2. Measurement Quantities and Classification Framework

The framework first separates the reported biochemical variable or analytical endpoint from the architecture used to obtain it. Only after specifying both the proximal analyte-defining event and the applicable calibration model can the resulting quantity be defined as the reportable endpoint. Accordingly, the framework recognizes the following primary endpoints: unresolved endogenous NAD(P)H-associated contrast; recovered NADPH, NADP⁺, total NADP(H), or a derived ratio; sensor-accessible NADPH or NADP⁺; an NADPH/NADP⁺ concentration-ratio response; a relay-defined NADP(H) response; and integrated NAD(P)H-dependent chemical reactivity. None of these endpoints should be treated as analytically interchangeable.

Once the reported endpoint has been fixed, the framework maps each platform across four descriptive dimensions: the analyte-defining event, optical transduction or readout, acquisition modality, and deployment context. Within the optical layer, photophysical transduction mechanisms are distinguished from the observable variables used to quantify them; otherwise, these dimensions remain conceptually independent and may coexist within a single platform. The analysis then treats reversibility, operating range, calibration, and confounding variables as context-dependent properties rather than additional measurement classes.

Primary classification follows the proximal analyte-defining event—not wavelength, fluorophore family, or biological application. Multiplexed platforms therefore require separate classification of every independently calibrated channel. Changing the transduction, acquisition, or deployment layer does not, by itself, alter analyte identity; accordingly, the least well-validated link in the measurement chain sets the limit on the recommended reporting term.

Throughout this review, sensor-accessible NADPH or NADP⁺ denotes the fraction able to interact with a sensor under its stated affinity, localization, competition, and time scale; the term should not be equated automatically with a thermodynamic free concentration. For the same reason, concentration ratio, relay-defined response, sensor redox state, and thermodynamic redox potential remain distinct terms rather than interchangeable synonyms.

Figure 2 provides the architecture-level overview for this sequence: label-free methods preserve native spatial context, extraction and enzyme-coupled assays emphasize recovered-pool or turnover measurements, protein-defined systems report binding, assembly, relay, or ratio events, and reaction-based small molecules emphasize chemically integrated optical responses. These families are non-exclusive and are not intended as a ranking of molecular specificity. The framework was organized as a constrained sequence of inference: the reportable endpoint was defined; the proximal analyte-defining event was identified; optical transduction was separated from acquisition; the measurement was placed in its sample environment; and the proposed interpretation was then tested. Validation was positioned last to determine whether that interpretation survived the relevant operating range, competing cofactors, matrix effects, calibration demands, and orthogonal comparison. A platform could therefore be multimodal without becoming multi-analyte, and broader deployment did not confer stronger chemical recognition (Figure 2).

Figure 2. Analytical architectures used for NADPH-related optical measurements. Label-free imaging preserves native spatial context; extraction and enzyme-coupled assays provide recovered-pool or turnover measurements; protein-defined systems report binding, relay, ratio, or assembly events; and reaction-based small molecules provide flexible optical formats. These non-exclusive architecture families orient the comparison; definitive assignment follows the reported endpoint and proximal analyte-defining event.

Table 1 provides an initial, non-exclusive orientation by architecture family, whereas Table 2 serves as the master map linking named platforms to their reported endpoints, analyte-defining events, readouts, deployment settings, and recommended terminology. Later mechanism- and context-specific tables address protein-defined sensing, reaction chemistry and product evidence, acquisition-specific performance, and biological claim boundaries. These tables are complementary rather than cumulative or evaluative. A platform may therefore appear in more than one table because a different analytical question is being asked, not because the platform has been counted twice or assigned greater evidentiary weight.

Table 1. Non-exclusive architecture-family overview of optical methods for NADPH and the NADP(H) redox system.

Architecture Family	Reported Endpoint	Analyte-Defining Event	Typical Readout	Reversibility	Principal Strength	Principal Limitation
Endogenous label-free measurement	NAD(P)H-associated intensity, lifetime, or phasor metric	Endogenous reduced-nicotinamide fluorescence and binding environment	Intensity, lifetime fit, or phasor coordinate	Non-reactive; repeatable within phototoxicity limits	Native spatial information without added probe	NADH/NADPH separation is model-dependent; not a universal absolute concentration assay
Extraction/enzyme-defined assay	Recovered NADPH, NADP+, total NADP(H), or derived ratio	Extraction followed by enzyme-defined turnover or cycling	Absorbance or fluorogenic reporter	Endpoint or time-resolved turnover	Strong chemical definition under controlled recovery and calibration	Compartment information is lost; recovery and coupling dominate interpretation
Protein-defined binding or assembly sensor	Sensor-accessible NADPH or NADP+ binding/occupancy	Engineered cofactor-binding environment or ligand-induced assembly	Intensity, ratiometry, FRET, or anisotropy	Usually reversible	Mechanistically defined recognition with genetic or chemigenetic targeting	Affinity, expression, pH, maturation, stoichiometry, and sensor buffering
Protein-defined relay or ratio sensor	NADPH/NADP+ concentration-ratio response or relay-defined NADP(H) response	Reversible ratio-sensing architecture or redox relay	Fluorescent-protein ratio or sensor redox response	Reversible	Compartment-resolved redox dynamics	Concentration ratio, relay response, sensor redox state, and redox potential require separate calibration models
Reaction-based small-molecule probe	Integrated NAD(P)H-dependent chemical reactivity	Hydride transfer to an electrophilic acceptor	Turn-on, ratiometry, NIR, two-photon, or photoacoustic output	Generally irreversible	Broad spectral and deployment flexibility	Most are NAD(P)H-responsive; endpoint depends on kinetics, loading, matrix, and product accumulation
Coupled reporter assay	Residual or regenerated NAD(P)H after enzyme turnover	Coupled enzymatic turnover and reporter conversion	Fluorogenic plate or microdroplet endpoint	Assay-dependent	High-throughput enzyme-library compatibility	Not a direct intracellular cofactor sensor; coupling stoichiometry and sorting fidelity are central

Table 2. Representative named platforms, reported endpoints, and recommended reporting terms.

Platform	Reported Endpoint	Analyte-Defining Event	Transduction	Reversible	Recommended Reporting Term	Representative Deployment	Key Unresolved Issue
mBFP	NADPH-associated protein-binding response	Protein-defined NADPH binding	Binding-dependent intensity enhancement	Rapid response; reversibility and in-compartment calibration are format-dependent	NADPH-preferential protein-defined binding under reported purified conditions	Purified assay, bacteria, plant stroma	Expression, pH, concentration, and buffering in cells
iNap	Sensor-accessible NADPH binding response	Engineered NADPH-binding domain	Ratiometric fluorescent protein	Yes	Protein-defined sensor-accessible NADPH sensor	Cytosol and targeted organelles	Affinity range, pH correction, expression, and sensor buffering
NERNST	Relay-defined NADP(H) response	NTRC-mediated redox relay	roGFP2 ratio	Yes	NADP(H)-linked redox-relay sensor	Bacteria, plants, animals, organelles	Relay kinetics, thiol-network coupling, and redox calibration
NAPstar	Calibrated NADPH/NADP+ concentration-ratio response	Engineered reversible ratio sensing	Ratiometric fluorescent protein	Yes	NADPH/NADP+ concentration-ratio sensor within a variant-specific range	Yeast, plants, mammalian cells	Variant operating range, pH, and equilibrium assumptions
Apollo-NADP+	Sensor-accessible NADP+ binding/occupancy	NADP+-dependent homodimerization	homoFRET/anisotropy	Yes	Protein-defined NADP+ binding sensor	Cells, organelles, zebrafish	Sensor concentration, equilibrium, and polarization calibration
FOCS-NADPH	NADPH-associated binding response in an eDHFR-defined environment	eDHFR-defined cofactor binding	Ratiometric heteroFRET	Yes; few-second reversible response reported	NADPH-preferential protein-defined binding response	Live-cell cytosol	Mixed-cofactor evidence, component stoichiometry, ligand delivery, and buffering
NAFP4	Integrated reduced-cofactor reactivity	Quinolinium hydride transfer	Turn-on fluorescence	No	NAD(P)H-responsive	Mitochondria-associated infection model	Membrane potential, loading, and product accumulation
Sensor A	Integrated reduced-cofactor reactivity	Quinolinium hydride transfer	Visible/NIR ratio	No	NAD(P)H-responsive	Cells, tissue, Drosophila	Mixed competition and fixed-time bias
CKD-pro	Biofluid reaction endpoint	Dual-salt hydride transfer	Turn-on fluorescence	No	NAD(P)H-responsive	Hypoxic renal models and urine cohort	Matrix recovery, inner filter, and clinical covariates
ISQM	Integrated mitochondrial reaction signal	Methylquinolinium hydride transfer	Deep-red turn-on	No	NAD(P)H-responsive	Cells and in vivo mitochondrial imaging	Membrane potential and product retention
TQ1	Integrated reaction plus product redistribution	Quinolinium hydride transfer and trafficking change	Deep-red redistribution signal	No	NAD(P)H-responsive	Dopaminergic-toxicity models	Product identity and nucleus/nucleolus affinity
Rh-DD-QL	Integrated reaction signal	Quinolinium hydride transfer	NIR fluorescence/photoacoustic	No	NAD(P)H-responsive unless mixed competition supports stronger wording	tumor cells, tissue, mice	Biodistribution, attenuation, and photoacoustic normalization
NATP-3	Integrated hydride-transfer reaction signal	Quinolinium hydride transfer	Two-photon-excited red fluorescence (1010 nm excitation; ~635 nm emission)	No	NADPH-sensitive under the reported isolated-cofactor panel; NADPH selectivity is not established in mixed backgrounds	Brain cells and mitochondrial-dysfunction models	Mixed-cofactor competition, loading, power, depth definition, and product accumulation
SAFRAN	Residual NAD(P)H after coupled turnover	Enzyme-coupled reporter conversion	Fluorogenic droplet endpoint	Assay-defined	NAD(P)H-responsive coupled-assay reporter	Directed enzyme evolution	Coupling stoichiometry and sorting fidelity

Throughout Tables 2–5, “not identified” means only that the relevant information was not located in the cited primary article or accessible supplementary information associated with the cited primary article. The framework does not convert missing documentation into a negative capability claim, nor does it infer molecular non-selectivity solely from the absence of a particular experiment. Conversely, a recommended reporting term remains bounded by the concentrations, matrices, compartments, time scales, and validation conditions actually examined; it should not be generalized beyond those limits.

With the endpoint vocabulary and mapping rules now fixed, the analysis can move from classification to causation. The first question in the measurement chain is not how bright, deep, or convenient a platform appears, but which event actually couples the optical system to NADPH, NADP+, or unresolved NAD(P)H. Section 3 therefore resolves recognition before performance, preventing downstream signal quality from being mistaken for molecular identity.

3. Analyte-Defining Events

What an optical platform can legitimately claim to measure follows from its analyte-defining event. That event may involve endogenous chromophore emission, enzyme-defined turnover, protein–cofactor binding, ligand-induced assembly, a redox relay, or irreversible hydride-transfer chemistry. Even when they generate similar intensity or ratio changes, these mechanisms remain analytically non-interchangeable. Accordingly, this section focuses on analyte-defining mechanisms, leaving downstream photophysics and deployment-specific controls to Section 4, Section 5 and Section 6.

3.1. Endogenous Reduced-Pyridine-Nucleotide Optical Signals

NADH and NADPH share the intrinsic fluorescent reduced nicotinamide chromophore; therefore, their endogenous fluorescence spectra overlap extensively. Conventional blue autofluorescence therefore warrants the broader NAD(P)H designation unless a validated lifetime or multivariate model supports a narrower assignment; even under those conditions, the result remains model-dependent and should not be converted directly into an absolute free-NADPH concentration [20,21,22,34].

Cofactor abundance alone does not determine intensity; quantum yield, enzyme binding, optical path length, mitochondrial content, and oxygenation also contribute [20,34,35]. Scattering, photobleaching, segmentation, and acquisition settings further broaden that variation [36,37]. Consequently, endogenous intensity constitutes a composite optical phenotype rather than a stoichiometric measurement of free NADPH [20,34].

FLIM adds sensitivity to the cofactor-binding environment; however, the familiar two-component free/bound model remains an operational approximation [21,22,38]. Enzyme-bound lifetimes span multiple conformations, while changes in pool size or redox-dependent binding equilibria can reshape lifetime maps without tracking any single cofactor concentration [38,39,40]. As illustrated in Figure 3A,B, the shared reduced-nicotinamide chromophore produces substantial spectral overlap, whereas Figure 3C,D show that lifetime analysis reflects binding-environment and pool-state changes rather than a one-to-one readout of a single cofactor concentration [20,22].

Figure 3. Endogenous NAD(P)H optical origin and label-free imaging. (A) NADH and NADPH share the fluorescent reduced nicotinamide chromophore, whereas NADPH contains an additional 2′-phosphate. (B) Spectral measurements provide aggregate reduced-pyridine contrast. (C) FLIM reports binding-environment-dependent lifetime distributions. (D) Pool-size and binding-state changes can reshape mitochondrial lifetime maps without mapping one-to-one onto a single cofactor concentration. Reproduced with permission [21,22,39]. In (A), a and b denote NADH and NADPH, respectively. In (B), the magenta trace is the measured aggregate spectrum and the colored curves are the NNMF-resolved components. In (C), blue, red, and green bars denote mitochondria, cytosol, and nucleus, respectively; asterisks indicate statistically significant differences reported in the source studies. In (D), the false-color bars encode mean lifetime (τmean), and the white scale bars denote 10 μm.

3.2. Enzyme-Defined Turnover and Coupled Assays

Rather than sensing sensor-accessible intracellular NADPH directly, enzyme-coupled assays infer an endpoint through a defined reaction sequence. Depending on the extraction and coupling design, that endpoint may correspond to NADPH, NADP⁺, total NADP(H), or a calculated ratio; cycling assays amplify the signal by regenerating NADPH and coupling it to a secondary reporter. Accordingly, enzyme-mediated turnover defines the analyte, whereas recovery and matrix effects enter later as context-dependent variables addressed in Section 5 and Section 6 [16,41]. Figure 4A illustrates cycling amplification, Figure 4B the G6PD-linked microfluidic fluorescence format, Figure 4C the influence of extraction conditions on apparent NADPH and NADP+ recovery, and Figure 4D the recovery and calibration steps that define how the extracted quantity is interpreted.

Figure 4. Enzyme-coupled and extracted-sample NADP(H) assay formats. (A) Cycling amplification. (B) glucose-6-phosphate dehydrogenase (G6PD)-linked microfluidic fluorescence. (C) Extraction conditions alter apparent NADPH and NADP⁺ recovery. (D) Recovery experiments and calibration define how the extracted quantity is interpreted. Reproduced with permission [41]. In (C), horizontal error bars show the variability reported in the source data; negative tick labels are presented with mathematical minus signs.

Microfluidic G6PD assays demonstrated that this architecture could deliver rapid analysis from low sample volumes [41]. SAFRAN, by contrast, provided a fluorogenic endpoint for residual NAD(P)H after enzyme-catalyzed turnover during microdroplet sorting. Thus, it functioned as an enzyme-coupled screening reporter rather than a freely diffusible intracellular NADPH probe [30].

3.3. Protein-Defined Binding of Sensor-Accessible NADPH

Protein-defined systems encompass several recognition architectures rather than a single design principle. Under the reported conditions, purified cofactor panels supported preferential NADPH binding by mBFP, although direct recognition of the 2′-phosphate was not demonstrated. By comparison, iNap was derived from a natural NADPH-binding domain, whereas FOCS-NADPH positioned the cofactor within an engineered dihydrofolate reductase (eDHFR)-defined environment. These examples underscore the need to distinguish direct structural recognition from mutational or biochemical support and from response-based selectivity [19,28,42].

Purified mBFP produced a rapid fluorescence increase upon NADPH binding, with selectivity assessed against NADH, NAD⁺, and NADP⁺ under defined conditions. Subsequent expression in bacteria and plant stroma extended the same binding-defined scaffold to living systems without altering the proximal recognition event [42,43,44,45]. Figure 5A,B show expressed mBFP during bacterial metabolic perturbations, Figure 5C shows the purified binding-dependent fluorescence assay, and Figure 5D shows targeted stromal measurements in plants; together, the panels illustrate how the same proximal binding event is retained while the calibration environment changes.

Figure 5. Protein-defined mBFP measurement formats. (A,B) Expressed mBFP followed NADPH-associated changes during bacterial metabolic perturbations. (C) Purified mBFP provided a rapid binding-dependent fluorescence assay. (D) Targeted expression followed stromal NADPH-associated dynamics in plants. The panels illustrate how calibration and matrix differ across applications of the same scaffold. Reproduced with permission [42,43,44,45].

iNap couples an engineered NADPH-binding domain to a circularly permuted fluorescent protein. Although individual variants span different affinity windows, each reports a protein-defined, sensor-accessible NADPH binding response rather than a universal thermodynamic free concentration [19,46,47].

FOCS-NADPH places the cofactor within an eDHFR-defined environment coupled to chemigenetic fluorophores. Here, the protein environment defines recognition, whereas heteromolecular Förster resonance energy transfer (heteroFRET) serves only as the downstream readout [28].

3.4. Sensor-Accessible NADP⁺ Binding Through Ligand-Induced Dimerization

Apollo-NADP⁺ was developed to report sensor-accessible NADP⁺ through ligand-dependent homodimerization of an enzymatically inactive G6PD-derived domain. Although homomolecular Förster resonance energy transfer (homoFRET) and steady-state anisotropy provided the optical response, NADP⁺ binding and dimer formation—not energy transfer itself—constituted the analyte-defining event [18,48].

Apollo measurements informed NADP(H) analysis without directly quantifying sensor-accessible NADPH, hydride-transfer reactivity, a concentration ratio, redox potential, or total NADP(H). Instead, NADP⁺-dependent dimerization defined the measured event [18,48].

3.5. Comparison of Protein-Defined Sensor Architectures

Figure 6A identifies iNap as a sensor-accessible NADPH-binding platform, Figure 6B shows the NERNST NTRC-mediated redox relay, Figure 6C shows reversible NADPH/NADP⁺ concentration-ratio sensing by NAPstar, and Figure 6D shows Apollo-NADP⁺ ligand-dependent dimerization detected by homoFRET and anisotropy. By contrast, Table 3 restricted the comparison to these protein-defined platforms, and the distinction among sensor-accessible cofactor binding, relay-defined redox transfer, and calibrated concentration-ratio sensing was preserved.

Figure 6. Distinct protein-defined analyte-defining mechanisms. (A) iNap reports sensor-accessible NADPH binding. (B) NERNST couples an NADPH-dependent thioredoxin reductase C (NTRC)-mediated redox relay to reduction–oxidation-sensitive green fluorescent protein 2 (roGFP2). (C) NAPstar variants provide reversible NADPH/NADP⁺ concentration-ratio sensing. (D) Apollo-NADP⁺ reports sensor-accessible NADP⁺ through ligand-dependent dimerization detected by homoFRET and anisotropy. Reproduced with permission [14,19,48,49].

Table 3. Comparison of protein-defined NADP(H)-related sensing architectures.

Platform	Analyte-Defining Event	Reported Endpoint	Optical Readout	Operating Behavior	Critical Validation and Principal Confounders
mBFP [42,43,44,45]	Protein-defined NADPH binding	NADPH-associated protein-binding response	Intensity enhancement	Rapid binding; reversibility and in-compartment calibration are format-dependent	Purified affinity/selectivity panel; protein concentration, expression, pH, targeting, and buffering
iNap [19]	Engineered NADPH binding	Sensor-accessible NADPH response within a variant-specific affinity range	Ratiometric fluorescent protein	Reversible variants	In situ calibration and pH correction; expression, maturation, targeting, affinity range, and sensor buffering
FOCS-NADPH [28]	NADPH binding in an eDHFR-defined environment	NADPH-preferential protein-defined binding response	Reversible heteroFRET ratio	Few-second reversible response reported	Mixed-cofactor testing, donor/acceptor stoichiometry, ligand delivery, affinity, pH, and buffering
NERNST [14]	NTRC-mediated NADP(H)-linked redox relay	Relay-defined NADP(H) response	Ratiometric roGFP2 redox response	Reversible relay response	Redox calibration and relay characterization; thiol environment, glutathione/glutaredoxin coupling, kinetics, and pH
NAPstar [15,49]	Engineered reversible NADPH/NADP+ sensing	Calibrated concentration-ratio response within a variant-specific range	Ratiometric fluorescent protein	Reversible	Variant calibration and compartment perturbation; expression, pH, maturation, equilibrium assumptions, and operating range
Apollo-NADP+ [18,48]	NADP+-dependent homodimerization	Sensor-accessible NADP+ binding/occupancy	homoFRET/anisotropy	Reversible dimerization	Dimerization and anisotropy calibration; sensor concentration, polarization optics, pH, scattering, and equilibrium assumptions

NERNST couples NADP(H)-linked chemistry to roGFP2 through an NTRC-mediated redox relay. Relay-mediated redox transfer therefore defines the proximal event, supporting a relay-defined NADP(H) redox response rather than direct free-NADPH binding [14].

NAPstar variants provide reversible sensing across variant-dependent NADPH/NADP⁺ ratio ranges. Accordingly, they report ratio or redox-state changes rather than an unqualified NADPH concentration [15,49].

Even superficially similar normalized optical outputs become quantitatively comparable only after the reported endpoint and calibration model have been stated explicitly.

3.6. Hydride-Transfer Chemistry in Reaction-Based Probes

Reaction-based probes demand a distinct analyte-defining framework because recognition consumes the reduced cofactor and yields an accumulated chemical product. Consequently, the reacting cofactor set and the evidence for product identity—not the downstream wavelength or imaging modality—govern the supported reporting term. Table 4 compares representative reaction-based probes in terms of reaction chemistry, product evidence, and cofactor-discrimination evidence.

Table 4. Reaction chemistry, product evidence, and cofactor-discrimination evidence for representative probes.

Platform	Analyte-Defining Event	Reported Endpoint	Product Evidence	NADH/NADPH Discrimination	Critical Validation/Confounders
NAFP4 [50]	N-methylquinolinium hydride transfer	Accumulated NAD(P)H-responsive reaction signal	Formal reduced product proposed; isolated-product analysis not identified	NADH interference panel only; mixed-cofactor specificity not established	Loading, membrane potential, mitochondrial mass, viability, and exposure time
Sensor A [29]	3-Quinolinium hydride transfer	Accumulated visible/NIR ratiometric reaction signal	1,4-Dihydroquinoline product reported	Separate-cofactor tests; simultaneous competition not identified	Channel registration, differential bleaching, uptake, attenuation, and fixed-time bias
CyQ [51]	Hydride-responsive quinolinium channel plus nitroreductase channel	Two reaction-channel endpoints with independent kinetics	Product analysis not reported for the NAD(P)H channel	NADH comparison not reported for the NAD(P)H channel	Cross-talk, channel balance, bacterial burden, and inflammatory background
CKD-pro [31]	Dual-salt quinolinium/thiazolium hydride transfer	Matrix-dependent biofluid reaction endpoint	Selectivity and recovery characterization; isolated-product evidence not identified	Selectivity panel reported; simultaneous NADH/NADPH competition not identified	Urine pH, specific gravity, inner-filter effects, recovery, medications, and renal covariates
ISQM [52]	Methylquinolinium hydride transfer with mitochondrial accumulation	Accumulated deep-red mitochondrial reaction signal	Isolated-product evidence not identified	Cofactor panel reported; matched mixed-cofactor competition not identified	Membrane potential, mitochondrial mass, product retention, morphology, and exposure time
TQ1 [53]	Quinolinium hydride transfer coupled to charge and trafficking change	Reaction signal followed by product redistribution	Product identity remains distinct from trafficking evidence	Matched mixed-cofactor competition not identified	Membrane potential, product identity, nuclear/nucleolar affinity, morphology, and time
NADH-R [54]	Quinolinium hydride transfer	Reaction signal with precursor/product redistribution	Product localization and identity require separation	Reporting should follow the exact primary cofactor conditions	Precursor/product localization, uptake, tissue attenuation, retention, and acquisition time

Most reaction-based probes considered here incorporate electron-deficient quinolinium or pyridinium acceptors [23,24,25,26]. Formal hydride addition from the reduced nicotinamide ring generates a dihydroheteroaromatic product while reorganizing the donor–acceptor electronic structure [24,25,29]. Mitochondria-targeted and redistribution formats translate this chemistry into intracellular imaging [50,52,53,55]. Ratiometric, biofluid, two-photon, and in vivo near-infrared (NIR) designs further adapt the same chemistry to distinct acquisition and deployment settings [29,31,33,56]. Because NADH and NADPH share the reactive hydride donor, these systems generally warrant an NAD(P)H-responsive classification unless stronger evidence supports a narrower assignment; Section 6.2 consolidates the required discrimination tests.

Across probe families, N-alkylation, π-extension, bridge identity, and substituent electronics have served to tune electrophilicity, solubility, membrane permeability, aggregation, photostability, reaction rate, and product emissivity [23,26,57,58]. Although such changes can improve analytical contrast or tissue compatibility, they leave the analyte-defining event unchanged; improved imaging performance therefore cannot be taken automatically as evidence of improved cofactor specificity [50,59,60].

The strength of product evidence varied markedly across platforms. NATP-3 underwent high-performance liquid chromatography (HPLC), nuclear magnetic resonance (NMR), and high-resolution mass spectrometry (HRMS) characterization of the reduced product NATP-3H; Sensor A was reported to form a 1,4-dihydroquinoline product; and Rh-DD-QL was evaluated by HPLC–MS [29,33,61]. Figure 7A illustrates electrophilic quinolinium reduction in NATP-3, Figure 7B links product formation to long-wavelength fluorescence, and Figure 7C shows mitochondria-associated deployment of NAFP4, thereby separating recognition chemistry from downstream photophysics and localization.

Figure 7. Representative hydride-transfer architectures. (A) NATP-3 illustrates electrophilic quinolinium reduction. (B) Product formation yields long-wavelength fluorescence. (C) NAFP4 illustrates mitochondria-associated deployment after reaction-based activation. The panels distinguish recognition chemistry, photophysics, and localization. Reproduced with permission [50,62]. Within (C), (a), (b), and (c) denote the merged, NAFP4, and Mito-Tracker channels, respectively.

Having separated the analyte-defining mechanisms, the review can now follow the signal downstream. Section 4 traces how binding, assembly, relay, enzyme turnover, endogenous emission, or hydride transfer becomes an intensity, ratio, lifetime, nonlinear, or acoustic readout, while retaining analyte identity as an upstream constraint. The distinction is essential: optical engineering can improve sensitivity, normalization, penetration, or temporal access without necessarily strengthening chemical specificity.

4. Optical Transduction and Acquisition

Optical transduction governs how an analyte-defining event becomes measurable, whereas acquisition governs how the resulting signal is collected. To avoid conflating these levels, Section 4 distinguishes the photophysical mechanism that converts the upstream event into an optical change from the experimentally observed variable used to quantify that change. Neither layer redefines analyte identity: the same hydride-transfer reaction can support fluorogenic, ratiometric, NIR, two-photon, or photoacoustic outputs, and similar optical changes can arise from unrelated binding, relay, or lifetime mechanisms. Accordingly, Section 4.1 focuses on fluorogenic and excited-state transduction mechanisms, Section 4.2 and Section 4.3 consider the resulting ratiometric, anisotropy, lifetime, and phasor readouts, and Section 4.4 addresses extended-depth and multimodal acquisition.

4.1. Fluorogenic and Excited-State Transduction Mechanisms

At the signal-transfer level, turn-on fluorescence offers experimental simplicity and rapid imaging; however, absolute intensity remains sensitive to probe concentration, illumination, focal plane, detector gain, compartment volume, bleaching, and product retention [50,63,64,65]. In irreversible systems, reaction time and product accumulation further shape the signal, thereby making exposure history part of the measurement [24,25,50]. Chemigenetic intensity changes introduce a parallel requirement for expression and ligand-delivery controls [28].

‘Fluorogenic’ identifies how a signal appears, not which species the platform recognizes. NAFP4 and CKD-pro rely on hydride-transfer chemistry, whereas SAFRAN reports residual cofactor after enzyme-coupled turnover. Grouping them solely on the basis of fluorescence enhancement would therefore obscure the different quantities underlying their signals [30,31,50].

Aggregation-induced emission (AIE)-based systems introduce an additional dependency because aggregation and restricted intramolecular motion modulate emission. Consequently, the reported responses of Ir1/Ir2 to NADH and NADPH should be interpreted in light of solvent composition, ionic strength, protein binding, aggregate state, and cellular uptake rather than attributed to cofactor concentration alone [66,67].

Pairing intensity measurements with an independent reference channel, internal loading standard, or calibrated lifetime readout improves reliability [63,64,65]. Even so, such normalization corrects only selected optical sampling errors and cannot eliminate dependence on reaction time, localization, or expression [18,24,25,50].

Intramolecular charge transfer (ICT) and photoinduced electron transfer (PeT) refer to changes in excited-state electronic coupling; twisted intramolecular charge transfer (TICT) denotes a twisted charge-transfer state, whereas AIE denotes emission enhancement driven by restricted motion or aggregation. FRET belongs at the same photophysical level insofar as analyte-dependent donor–acceptor proximity or assembly changes the efficiency of excited-state energy transfer. Despite producing superficially similar turn-on signals or wavelength shifts, these mechanisms remain non-interchangeable [62,66,67,68].

Hydride addition can reorganize donor–acceptor strength and suppress or enable ICT or PeT pathways, thereby shifting fluorescence intensity or wavelength [23,26,29,57]. Related quinolinium and multimodal systems demonstrate how a common reaction can feed distinct optical outputs [56,61]. Yet polarity, viscosity, protonation, aggregation, protein binding, and conformational restriction can generate similar spectral changes [55,60,66,67]. Robust mechanistic assignment therefore requires structural and spectroscopic evidence beyond the emission trace alone [62,68].

Hydride-triggered electronic reorganization was linked to fluorescence, photoacoustic conversion, and a general TICT benchmark, while ground-state recognition was separated from excited-state photophysics and the final imaging modality (Figure 8). This comparison avoided implying that every output arose through a single pathway [61,62].

Figure 8. Relationships among hydride transfer, donor–acceptor electronic reorganization, fluorescence, photoacoustic conversion, and TICT behavior. The scheme distinguishes the recognized chemical event from downstream photophysics and the final imaging modality. (A) Hydride transfer converts the electrophilic acceptor into the reduced donor–acceptor product and shifts the absorption/emission response. (B) Relative-response selectivity panel; the final bar corresponds to NADPH and the remaining bars to comparator substances listed in the source study. (C) NADH-dependent cellular imaging under control, 5, 20, and 50 μM conditions; Channel I was acquired at Ex 633 nm/Em 700–780 nm, Channel II is bright field, and the lower row shows merged images; white bars denote microscopy scale bars. (D) TICT benchmark showing the locally excited-to-TICT conformational switch and solvent-polarity-dependent emission; colored curves correspond to the solvent legend. Reproduced with permission [61,62].

4.2. Ratiometric and Anisotropy-Based Readouts

Ratiometry and anisotropy are treated here as observable variables rather than fluorescence-modulation mechanisms; either can report an upstream FRET or non-FRET transduction event. Ratiometry suppresses selected common-mode errors only when both channels bear a defined relationship to the measured event [29,57]. Even then, background subtraction, channel registration, bleed-through correction, excitation balancing, detector-linearity checks, and differential-bleaching controls remain necessary; a ratio does not become self-calibrating merely by construction [64,65,69,70]. Open-source platforms such as Fiji and ImageJ2 can support documented channel registration and ratio processing; nevertheless, preprocessing parameters and decision rules still require explicit reporting [71,72]. Although dual-channel discrimination has been demonstrated for other closely related analyte classes, those analyte-specific recognition schemes do not establish NADH/NADPH selectivity [73].

Sensor A converted quinolinium reduction into reciprocal visible and NIR signals, whereas quinolinium-functionalized hemicyanines used bridge and receptor modifications to generate alternative visible/NIR ratios. In both cases, hydride transfer remained the recognition event: ratiometry altered the readout, not the cofactor chemistry [23,29,57].

Rh-O-QL couples a quinoline-based NAD(P)H-responsive reaction channel to a pH-dependent rhodamine equilibrium, whereas the quinoline multimodal indicator separates spectrophotometric and visible/NIR outputs [74,75]. Consequently, channel-specific calibration remains essential because pH, protonation, product formation, and spectral cross-talk can alter the ratio independently of NAD(P)H [64,65,74]. Figure 9A shows visible/NIR ratiometry in Sensor A, Figure 9B illustrates coupling of a hydride-responsive channel to a pH-sensitive rhodamine equilibrium, Figure 9C summarizes compact coumarin-based fluorogenic or ratiometric outputs, and Figure 9D distinguishes SAFRAN as an enzyme-coupled residual-NAD(P)H readout rather than a direct intracellular NADPH sensor [29,30,59,74].

Figure 9. Examples of non-equivalent optical signal formats. (A) Sensor A converts quinolinium reduction into a visible/NIR ratio. (B) Rh-O-QL combines a hydride-responsive channel with a pH-sensitive rhodamine equilibrium. (C) Coumarin-based probes provide compact fluorogenic or ratiometric outputs. (D) SAFRAN reports residual NAD(P)H in an enzyme-coupled microdroplet assay rather than free intracellular NADPH. Reproduced with permission [29,30,59,74].

FOCS-NADPH and Apollo-NADP⁺ both exploit energy transfer, although for fundamentally different analytical purposes. FOCS-NADPH employs heteroFRET between assembled donor and acceptor components, whereas Apollo-NADP⁺ relies on ligand-dependent homodimerization to alter homoFRET and anisotropy. Shared terminology, however, should not be mistaken for a shared calibration model. In this framework, FRET denotes the underlying energy-transfer mechanism, whereas donor/acceptor ratios or anisotropy are the experimentally measured variables through which that mechanism is quantified [18,28,48].

FRET-derived donor/acceptor intensity ratios reflect donor/acceptor stoichiometry, labeling efficiency, fluorophore maturation, direct acceptor excitation, spectral bleed-through, linker geometry, and concentration [28,63,76]. Anisotropy introduces further sensitivity to polarization calibration, rotational mobility, scattering, and optical depolarization [18,48,76]. These variables belong in the transfer function rather than in the definition of analyte selectivity.

For reversible sensors, dynamic range acquires meaning only when considered alongside response and recovery kinetics [63,76]. Indeed, a large steady-state ratio change may still fail to capture rapid biological transitions [18,28]. Concentration titrations and perturbations that drive the sensor toward both limits of its range therefore provide a more informative calibration [18,48,76].

Without an explicit correction scheme, raw FRET ratios and anisotropy values cannot be transferred reliably across instruments or expression levels [63,76]. Accordingly, reports should pair single-labeled controls with bleed-through and direct-excitation coefficients, polarization G-factor calibration, sensor-concentration or expression-range tests, and measurements near ligand-free and ligand-saturated limits [18,28,48]. Together, these controls distinguish occupancy- or assembly-dependent changes from optical cross-talk and convert a visually large response into a quantitatively comparable readout.

4.3. Lifetime and Phasor-Based Readouts

FLIM converts fluorescence decay into lifetime parameters that depend less strongly on fluorophore concentration than intensity does; nevertheless, binding, conformation, pH, quenching, instrument response, photon count, and the chosen fitting model still influence the result [21,22,34,38].

By representing lifetime mixtures without fixing the number of exponential components, phasor analysis offers particular value in heterogeneous cells, tissues, and organoids. Even so, biological assignment still requires perturbation experiments together with knowledge of other fluorophores, structures, and optical backgrounds within the field of view [20,34,77,78].

Under defined training and validation conditions, label-free lifetime studies can discriminate between NADH- and NADPH-enriched binding environments. Their outputs nevertheless remain sensitive to pool size and redistribution among enzyme-bound states; accordingly, they should be reported as model-dependent lifetime or phasor metrics rather than universal direct assays of absolute NADPH. Figure 10A illustrates redistribution of lifetime components by redox-dependent binding equilibria, Figure 10B shows phasor representation without imposing a fixed number of exponential components, and Figure 10C highlights multivariate optical-metabolic metrics for resolving cell-state heterogeneity [22,39].

Figure 10. Label-free lifetime and phasor readouts. (A) Redox-dependent binding equilibria redistribute lifetime components. (B) Phasor-FLIM represents mixtures without imposing a fixed number of exponentials. (C) Multivariate optical-metabolic metrics resolve cell-state heterogeneity. Reproduced with permission [27,39,78].

4.4. Extended-Depth and Multimodal Acquisition

Longer wavelengths, nonlinear excitation, and acoustic detection expand the depth and context over which a signal can be collected. Table 5 compares acquisition-specific performance while carrying the proximal event forward only as an interpretive anchor; Table 3 and Table 4 retain the detailed evidence for recognition chemistry and molecular specificity.

Table 5. Acquisition-focused comparison of long-wavelength, nonlinear, and photoacoustic platforms.

Platform/Modality	Proximal Event	Acquisition Format	Demonstrated Context	Acquisition-Relevant Evidence	Principal Modality/Deployment Confounders
KC8 [56]	Methylquinolinium hydride transfer	Turn-on NIR fluorescence near 745 nm	Cells and p53-associated in vivo model	Long-wavelength in vivo fluorescence under a fixed reaction protocol	Dose, uptake, protein binding, membrane potential, biodistribution, and product accumulation
Quinolinium hemicyanines [23,57,58,60]	Quinolinium hydride transfer	Turn-on or visible/NIR ratiometry	Cells, kidney tissue, Drosophila	Bridge-dependent spectral tuning and ratiometric collection	Channel balance, bleaching, polarity, viscosity, protein binding, uptake, and attenuation
Rh-DD-QL [61]	Quinolinium hydride transfer	NIR fluorescence plus activatable photoacoustic output	Tumor cells, tissue, mice	One reaction event collected through fluorescence and photoacoustic channels	Delivered energy, oxygenation, attenuation, acoustic reconstruction, biodistribution, and clearance
Compact 6-quinolinium cyanines [55,79]	Quinolinium hydride transfer	Deep-red/NIR turn-on or ratiometry	Live cells and diseased kidney tissue	Compact acceptors support tissue-facing long-wavelength imaging	Analogue identity, tissue thickness, background, uptake, pathology, and channel calibration
Benzopyrylium/cyanine analogues [26,58,60]	Electron-deficient donor-acceptor hydride-response architecture	Red-to-NIR turn-on fluorescence	Cells and tissue-facing imaging	Extended conjugation shifts absorption and emission	Bridge planarity, aggregation, polarity, viscosity, protein binding, and matrix effects
Rh-O-QL [74]	Hydride response plus pH-sensitive rhodamine equilibrium	Dual-parameter fluorescence	Mitochondrial-autophagy imaging	Two channels report a reaction endpoint and an independent equilibrium variable	pH cross-talk, unequal kinetics, membrane potential, loading, morphology, and registration
Quinoline multimodal indicator [75]	Quinoline-based hydride response	Spectrophotometry plus visible/NIR dual-channel fluorescence	In vitro and in vivo imaging	Multiple optical channels collected from one reaction architecture	Channel dependence, dose, reaction time, tissue background, and normalization
Coumarin-pyridinium probes [59,80]	Pyridinium/quinolinium hydride transfer coupled to coumarin ICT	Compact fluorogenic, red, or NIR output	Cells and Drosophila	Compact fluorophores enable varied excitation/emission windows	Autofluorescence, excitation wavelength, uptake, matrix, bleaching, and fixed-time endpoint
Ir1/Ir2 AIEgens [66,67]	Reduced-pyridine-nucleotide-associated response in aggregation-sensitive iridium systems	AIE-enhanced red/NIR luminescence	Aqueous media and cells	Aggregation-sensitive emission provides high contrast in selected media	Aggregate state, solvent fraction, ionic strength, protein binding, uptake, and mixed kinetics
NATP-3 [33]	Quinolinium hydride transfer	Two-photon excitation at 1010 nm; red emission near 635 nm	Brain cells and mitochondrial-dysfunction models	Nonlinear excitation improves spatial confinement under the reported settings	Power, phototoxicity, depth criterion, loading, membrane potential, scattering, and product accumulation
Label-free multiphoton/PA [27]	Endogenous NAD(P)H optical absorption and emission	Multiphoton fluorescence and photoacoustic detection	Brain cells, slices, cerebral organoids	Endogenous contrast collected at increasing depth without exogenous probe	Absorption, scattering, thermal confinement, tissue heterogeneity, photon statistics, and model dependence

NIR emission can reduce interference from visible background [23,26,55]. Two-photon excitation is treated here as an acquisition modality rather than an analyte-defining mechanism; its principal advantage is improved spatial confinement [33]. Photoacoustic detection further changes how signals are collected in scattering samples [27,61]. These benefits come with modality-specific requirements for attenuation, energy delivery, reconstruction, and calibration [24,32]. Moreover, tissue-facing cyanine and quinolinium systems remain sensitive to probe distribution and matrix effects [57,60,79].

NATP-3 coupled quinolinium reduction to two-photon excitation at 1010 nm, yielding red fluorescence near 635 nm [33]. Rh-DD-QL translated related chemistry into fluorescence and photoacoustic output [61], yet both remained reaction-based platforms whose interpretation depended on kinetics, competition, product identity, and matrix effects [24,25,33,61].

Any claim of deep imaging should specify the excitation or absorption wavelength, emission or acoustic band, delivered energy, focal geometry, tissue thickness, attenuation, background, signal-to-noise criterion, reconstruction method, and calibration standard [32,33,79]. By themselves, “two-photon,” “NIR,” and “photoacoustic” designate modalities rather than validated imaging depths [27,33,61].

Taken together, the preceding sections establish what each platform recognizes and how the resulting signal undergoes transduction and acquisition. Mechanism and modality alone, however, do not fix analytical meaning: once a method moves from controlled solutions into extracts, living cells, organelles, tissues, animals, biofluids, or screening droplets, sample-specific recovery, transport, localization, matrix, and optical constraints enter the measurement model. The next section therefore shifts the analysis from signal generation to measurement context, asking how deployment-dependent variables delimit the conclusions each platform can support.

5. Measurement Contexts and Context-Specific Constraints

Measurement context specifies where a signal is acquired and which physical, chemical, and biological conditions enter its interpretation. As a platform moves from buffer to extract, cell, organelle, tissue, animal, biofluid, or screening droplet, recovery, loading, expression, organelle state, optical attenuation, matrix composition, and temporal integration progressively reshape the measurement model. The following subsections examine those context-specific constraints, whereas Section 6 consolidates the corresponding cross-platform validation logic.

5.1. Purified and Extracted Samples

Purified assays offer the most controlled setting for defining affinity, reaction kinetics, spectral response, reversibility, and product identity because concentration, pH, ionic strength, temperature, and mixing can be manipulated directly [16,24,25]. Although such experiments establish intrinsic behavior under stated conditions, they do not reproduce cellular competition, macromolecular crowding, membrane partitioning, or endogenous binding [16,42].

Extracted samples, by contrast, introduce uncertainty through recovery, stability, internal-standard behavior, matrix-matched calibration, blank subtraction, and coupling efficiency [16]. Acid or base extraction, delayed quenching, and differential recovery can distort apparent NADPH and NADP⁺ values and therefore require protocol-specific characterization [16]. Stable-isotope tracing and carbon-13 flux analysis address pathway activity rather than extraction recovery; they should therefore be treated as orthogonal measurements [81,82,83]. Broader metabolomics reporting standards reinforce the same emphasis on sample handling, stability, and matrix documentation [84,85].

Validation of extracted samples should combine spike-recovery for both redox forms with time-to-quench studies, dilution linearity, and an explicit statement of whether the result represents a free pool, a total extracted pool, or an enzyme-defined equivalent [16,84,85]. Without these controls, analytical precision may coexist with biochemical inaccuracy [16].

When NADPH and NADP⁺ are measured separately, total NADP(H) and an explicit mass-balance or recovery calculation should provide an additional consistency check [16]. A ratio becomes defensible only when extraction, stability, and calibration have been validated independently for both numerator and denominator [16,84,85]. Stable-isotope internal standards, standard addition, and matrix-matched calibration can further separate extraction loss from ionization or optical suppression [84,85]. Nevertheless, none of these procedures can restore the compartment information lost during homogenization.

5.2. Live-Cell and Organelle-Resolved Measurements

In live cells, genetically encoded and chemigenetic formats bring dependencies on expression, maturation, stoichiometry, ligand delivery, pH, and sensor-induced buffering [18,19,28,46]. Small-molecule loading, together with any perturbation of the measured pool, introduces additional transfer-function uncertainty [50,63]. Acquisition, in turn, depends on illumination, registration, bleaching, segmentation, and phototoxicity [64,65,69,70]. Organelle-resolved measurements further add membrane potential, organelle mass, morphology, and localization stability to the set of context-dependent variables; Section 6.3 consolidates the corresponding controls [86,87,88].

Pathway perturbations often alter ATP, pH, oxygen consumption, redox balance, mitochondrial potential, and viability simultaneously [17,89]. Independent measurements of pool size or flux can therefore help separate route-specific metabolic effects from secondary changes [81,82,83]. Before assigning a directional optical response to a specific metabolic route, the evidence should therefore include rescue experiments and transparent reporting of the perturbation [90,91].

Compartment-specific calibration becomes indispensable near either boundary of a sensor’s operating range [18,19,46,47]. An absent or negative response may reflect saturation, insufficient occupancy, slow equilibration, or mistargeting [18,19,47]. Conversely, a large response may arise from sensor buffering or organelle-state changes rather than a proportional shift in the endogenous pool [50,86,87,88].

Organelle targeting constitutes a deployment feature rather than evidence of cofactor selectivity. Cationic and lipophilic probes, for example, commonly accumulate in polarized mitochondria [88,92]. Yet their localization also reflects plasma-membrane permeability, efflux, organelle volume, and intracellular binding [53,86,87]. Membrane-potential dependence must therefore be disentangled from analyte-dependent activation [86,87,88]. In parallel, respiratory-state-dependent mitochondrial reactive oxygen species (ROS) production can alter organelle physiology and fluorescence background independently of the target cofactor [93]. Lipophilic triphenylphosphonium systems further demonstrate how charge and membrane potential govern mitochondrial delivery [94].

A credible colocalization claim should combine loading controls, acute depolarization where appropriate, measurements of mitochondrial mass and morphology, and time-resolved tracking of precursor and product [86,87,88]. A high Pearson coefficient from a single image, by itself, cannot distinguish stable localization from transient entry, reaction-dependent trapping, or product redistribution [72,95].

Figure 11A separates the NADH-R precursor and reduced-product structures, Figure 11B links hydride-triggered electronic reorganization to red fluorescence, Figure 11C shows perturbation-dependent changes in the accumulated cellular signal, and Figure 11D demonstrates how intravital imaging further integrates reaction, transport, retention, and tissue attenuation. This panel sequence emphasizes why product trafficking must be distinguished from the site of the initial hydride-transfer event [53,54].

Figure 11. NADH-R as a reaction-based redistribution readout. (A) Probe and reduced-product structures. (B) Hydride-triggered electronic reorganization produces red fluorescence. (C) Cellular perturbations alter the accumulated signal. (D) Intravital imaging integrates reaction, transport, retention, and tissue attenuation. Reproduced with permission [54].

NATP-3, KC8, NAFP4, and ISQM have been deployed in mitochondria-associated cellular or disease models [33,50,52,56]. Nevertheless, cationic targeting does not guarantee a stable or exclusive mitochondrial population throughout acquisition [86,87,88,92]. Whenever localization underpins the biological claim, experiments should address depolarization, toxicity, altered morphology, and product migration explicitly [53,54,86,88].

5.3. Tissue-Level and In Vivo Imaging

Tissue and animal imaging expand the measurement model to include administration route, dose, biodistribution, clearance, plasma-protein binding, perfusion, oxygenation, scattering, absorption, depth, motion, segmentation, and reconstruction [32,61,79]. Platform-specific demonstrations expose the practical consequences of these pharmacokinetic and optical constraints [33,54,55,61]. Although longer wavelengths improve optical access, they do not eliminate tissue-state confounding [27,32,79].

A measured signal-to-background or reconstruction criterion should define imaging depth, with explicit linkage to excitation energy, tissue composition, and spatial resolution [27,33,61]. Ex vivo slices, superficial lesions, transparent organisms, and intact deep tissue therefore constitute non-equivalent demonstrations of depth [32,33,79].

Genetically encoded sensors permit controlled expression within selected cell types and compartments [14,15,18,19]. Small-molecule probes offer simpler administration, although they distribute more broadly across cells, organelles, and tissues [33,50,52,55]. Reaction-based platforms extend that flexibility through ratiometric and NIR designs [59,60,74,75]. Multimodal tumor-facing implementations further combine fluorescence, photoacoustic, and therapeutic outputs [61,96]. Figure 12A illustrates why compartment-specific fluxes cannot be inferred from bulk measurements; Figure 12B shows cytosolic and mitochondrial iNap dynamics; Figure 12C extends NERNST relay sensing across organisms; and Figure 12D illustrates Apollo-NADP+ anisotropy imaging in vivo; together, these panels keep targeting and recognition as separate design variables.

Figure 12. Deployment contexts for genetically encoded sensors. (A) Compartment-specific flux schemes illustrate why bulk measurements cannot localize a change; internal (i) and (ii) depict IDH-linked citrate/isocitrate cycling and serine/one-carbon metabolism, respectively. (B) Cytosolic and mitochondrial iNap variants resolve distinct local dynamics; the color bars encode the ratiometric sensor output. (C) NERNST time series display the ratiometric relay readout alongside bright-field and HyPerRed fluorescence; the color bar encodes the displayed ratio. (D) NAPstar measurements provide compartment-resolved concentration-ratio responses: (i) merged and ratio images (scale bar, 20 μm), (ii) NAPstar4.3 time course, and (iii) NAPstarC time course during DCMU/light perturbations. Reproduced with permission [14,15,17,19].

5.4. Biofluids and Clinical-Facing Assays

Figure 13A shows the capillary-driven microfluidic architecture integrating hemoglobin and G6PD measurements; Figure 13B shows fluorescence kinetics and calibration in diluted whole-blood lysate; Figure 13C shows classification across deficient, intermediate, and normal control samples; and Figure 13D shows positive and negative controls with temperature-normalized performance [41]. Biofluids, however, vary widely in pH, osmolality, protein and salt content, turbidity, hemolysis, lipemia, medication exposure, storage history, and freeze–thaw cycles. Any of these variables can alter reaction chemistry, fluorescence, absorbance, or recovery independently of the target cofactor.

Figure 13. Biofluid-facing assay implementation and validation. (A) Capillary-driven microfluidic architecture integrating hemoglobin and G6PD measurements. (B) Fluorescence kinetics and calibration of G6PD activity in diluted whole-blood lysate. (C) Classification using deficient, intermediate, and normal control samples. (D) Positive and negative controls with temperature-normalized performance. Within (C), (a) shows measured versus fitted G6PD activity and (b) compares measured and reference hemoglobin concentrations. Within (D), (c) shows the positive-control, test, and negative-control fluorescence kinetics, whereas (d) shows temperature-normalized slope ratios. The scale bar in (A) is 1 mm. Reproduced with permission [41].

Urine and other biofluid assays show particular sensitivity to dilution, pH, specific gravity, endogenous absorbers, medication, storage, and renal-function covariates [31,84,85]. These variables define the deployment context, while Section 6.3 consolidates the corresponding recovery, normalization, and reporting controls.

5.5. High-Throughput and Microdroplet Screening

High-throughput screening places priority on dynamic range, timing, well or droplet uniformity, sorting fidelity, false-positive control, and compatibility with the enzyme–substrate system. In this setting, a reporter may intentionally trade molecular resolution for speed, robustness, and enrichment efficiency [30].

SAFRAN therefore warrants evaluation through coupling stoichiometry, subsingle-turnover operation, enrichment, sorting accuracy, and library performance—not through criteria developed for intracellular imaging. Its output constitutes a residual-cofactor screening endpoint rather than a map of free NADPH in intact cells [30].

Screening studies should additionally document robustness across plates or droplet batches, positional effects, substrate depletion, carryover, and nonenzymatic reduction. Together, these controls reveal whether enrichment reflects the intended catalytic phenotype or merely instability within the coupled reporter system [30].

Because high-throughput endpoints prioritize ranking over mechanistic resolution, promising hits should undergo retesting in uncoupled assays that measure the primary reaction directly. Such retesting excludes variants that act on reporter chemistry, cofactor regeneration, or the droplet environment rather than on the intended enzyme reaction [30].

Across these measurement environments, the same platform can acquire different dominant error terms without changing its proximal analyte-defining event. Context therefore modifies the transfer function and the validation burden, not the underlying analyte identity. Section 6 converts those vulnerabilities into explicit tests, separating broadly applicable requirements—operating range, kinetics, and orthogonal confirmation—from mechanism- and context-specific controls.

6. Validation and Benchmarking

Only after defining the reported endpoint, analyte-defining event, optical transduction or readout, acquisition modality, and deployment context can validation establish which interpretation a signal supports. The sequence below separates operating-range characterization, molecular discrimination, context-specific controls, and orthogonal confirmation, thereby avoiding repetitive requirements across platform and application sections.

6.1. Operating Range, Kinetics, and Reversibility

Figure 14A shows the absorbance response to increasing NADH, Figure 14B the time-resolved emission spectra and channel ratio, Figure 14C the cellular ratiometric response across exogenous NADH concentrations, and Figure 14D the response to glucose-dependent metabolic perturbation. For binding sensors, adequate characterization included affinity or operating range, dynamic range, response and recovery times, reversibility, pH dependence, expression level, and in situ calibration. Reaction-based probes, by contrast, required a defined rate or endpoint metric together with product evidence and matrix-dependent recovery.

Figure 14. Concentration-, time-, and perturbation-dependent characterization of a ratiometric NAD(P)H probe. (A) Absorbance changes with increasing NADH. (B) Time-resolved emission spectra and channel ratio. (C) Cellular ratiometric response across exogenous NADH concentrations. (D) Cellular response to glucose-dependent metabolic perturbation. In (C,D), the white horizontal bars denote microscopy scale bars and the vertical color bars encode the displayed channel-I/channel-II ratio. Reproduced with permission [57].

Physiological relevance depends on both the reported endpoint and the compartment under study [1,2,17]. Consequently, extracted total pools cannot substitute directly for sensor-accessible cytosolic or mitochondrial concentrations [16,17]. Protein-defined systems instead report sensor-accessible NADPH or NADP⁺ within affinity- and concentration-dependent operating ranges [18,19,46,48]. Reversible relay and concentration-ratio sensors, in turn, report distinct redox variables [14,15,49]. Reaction-based probes integrate accessible reduced-cofactor reactivity over time [24,25,33]. Label-free lifetime methods, by contrast, add model-dependent information on binding-state distributions [20,22,39].

For reaction-based probes, product accumulation makes endpoint intensity a joint function of concentration and exposure time. Initial-rate measurements therefore provide the most informative basis for intrinsic kinetic discrimination; fixed-time endpoints suit screening or clinical workflows only when timing has been standardized explicitly [24,25].

6.2. Platform-Specific Molecular Discrimination

Molecular-discrimination tests must follow the analyte-defining event rather than a universal template. Thus, hydride-transfer probes require matched NADH/NADPH kinetics and simultaneous competition; protein-binding sensors require affinity, competition, and occupancy calibration; redox relays and concentration-ratio sensors require relay or equilibrium calibration; and label-free lifetime methods require model, instrument, and metabolic-perturbation validation. Mixed-cofactor competition becomes essential when a platform claims direct chemical discrimination; however, it cannot substitute universally for mechanism-specific validation.

No single NADPH/NADH ratio can represent all cells, organelles, or disease states [1,2,17]. Competition experiments should therefore span plausible absolute concentrations and reciprocal-excess conditions rather than rely on a single, arbitrarily chosen equimolar mixture [24,25].

Separate-cofactor tests establish intrinsic response under isolated conditions; nevertheless, they do not demonstrate preference in a mixed NADH/NADPH environment. The distinction becomes especially consequential for hydride-responsive quinolinium and related probes [23,26,29,57]. Stronger selectivity claims therefore require matched kinetics together with simultaneous competition at reciprocal-excess ratios [24,25]. Experience with ROS/RNS probes further demonstrates how reaction networks, competing species, and probe-derived chemistry can distort apparent selectivity [97,98].

A valid matched-kinetic comparison must hold buffer, pH, temperature, ionic strength, probe and cofactor concentrations, mixing, acquisition interval, and analytical metric constant. Otherwise, endpoints collected at different times—or pseudo-first-order conditions applied to only one cofactor—can create an artificial appearance of selectivity [24,25].

Physiological-background experiments should introduce the target cofactor into matrices containing relevant competing cofactors, nucleotides, reductants, proteins, salts, and pH conditions [24,25,99]. Because cytosol, mitochondria, plasma, urine, and tissue homogenates differ substantially, the term “physiological” requires an explicit definition rather than an implicit assumption [1,2,17]. Box 1 translates these requirements into a platform-agnostic benchmarking sequence.

Box 1. Benchmarking sequence for platforms that claim direct NADH/NADPH molecular discrimination.

Benchmark	Minimum Experiment	Interpretation Supported
Separate cofactor test	NADH and NADPH tested separately under stated buffer, pH, temperature, concentration and time	Basic reactivity or binding under isolated conditions only
Matched kinetic test	Same probe, buffer, cofactor concentration, mixing protocol and temporal resolution	Relative intrinsic response kinetics under the tested conditions
Simultaneous competition	NADH and NADPH present in the same reaction, including reciprocal excess conditions	Competitive preference in a defined mixed-cofactor environment
Physiological-background test	Target cofactor added within competitor-rich or matrix-matched backgrounds	Robustness to realistic chemical backgrounds; not universal cellular selectivity
Cellular perturbation	Pathway-selective genetic or pharmacological perturbation with uptake and organelle-state controls	Association of the optical change with a defined biological route
Orthogonal validation	Enzymatic assay, LC-MS, isotope tracing, FLIM or an independent sensor	Whether the optical readout tracks an independently measured metabolic change

The separate-cofactor, kinetic, and simultaneous-competition steps in Box 1 apply specifically to platforms claiming direct NADH/NADPH molecular discrimination. Binding, relay, ratio, and label-free platforms instead require evidence for the corresponding affinity, equilibrium, relay, or lifetime-model validity described above.

6.3. Context-Specific Calibration and Acquisition Controls

Context-specific controls should respond directly to the deployment problems defined in Section 5. Live-cell and organelle measurements therefore require localization, organelle-state, and loading controls [53,54,86,88]. Tissue imaging, by contrast, requires attenuation and reconstruction controls [32,61,79]. Biofluid assays add requirements for recovery, dilution linearity, matrix-matched calibration, and appropriate normalization [16,31,41]. Collectively, these checks establish robustness in the stated setting without, by themselves, identifying the reacting cofactor.

6.4. Orthogonal Validation and Minimum Reporting Standards

Orthogonal validation contributes most when it measures a complementary quantity rather than reproducing the same optical dependency. Enzymatic assays or LC–MS can corroborate changes in extracted pools, whereas isotope tracing can resolve flux [16,81,82,83]. FLIM and independent genetically encoded sensors can, in turn, provide label-free or compartment-resolved context [19,20,22,34]. Agreement strengthens interpretation, whereas disagreement may expose differences in accessible pool, calibration, uptake, or time scale.

Microscopy reports should document instrument configuration, objective, excitation power, detector settings, exposure, spectral windows, registration, background correction, segmentation, exclusion criteria, phototoxicity assessment, and the image-analysis workflow [38,63,64,65]. Channel processing and metadata should be described in sufficient detail to permit independent reconstruction [69,70]. Claims based on colocalization or representative images further require quantitative biological replicates and organelle-state controls [95]. Reproducible image analysis also demands explicit preprocessing parameters and decision rules [100,101,102]. Finally, phototoxicity should be assessed under the actual acquisition schedule rather than inferred from nominal illumination settings [103].

Figure 15A outlines the proposed hydride-triggered reaction and PeT modulation, Figure 15B the saturation response and low-concentration calibration, Figure 15C the time-dependent signal development, and Figure 15D the separate-analyte interference panel. Together, these measurements provide core analytical characterization; for reaction-based platforms, however, they cannot substitute for simultaneous mixed-cofactor competition. Binding, relay, ratio, and lifetime platforms instead require mechanism-specific affinity, equilibrium, relay, or model validation together with an orthogonal measurement of pool size or flux.

Figure 15. Core analytical characterization for a reaction-based NAD(P)H probe. (A) Proposed hydride-triggered reaction and PeT modulation. (B) Saturation response and low-concentration calibration. (C) Time-dependent signal development. (D) Separate-analyte interference panel. These measurements do not by themselves demonstrate mixed-cofactor discrimination. Reproduced with permission [23,29,33].

Validation closes the analytical portion of the framework but not the inferential chain. Once endpoint identity, recognition mechanism, readout, acquisition, context, and controls have been aligned, the remaining question becomes biological: what claim does the resulting signal actually justify? Section 7 therefore shifts from platform performance to claim discipline, treating physiology and disease as tests of interpretation rather than as additional sensor classes.

7. Biological Interpretation: Claims Supported by Current Evidence

Biological application does not create a new measurement class; rather, it tests whether a defined optical endpoint can sustain a specific biological inference. For NADPH-related measurements, this distinction is especially important because sensor-accessible NADPH, NADPH/NADP+ ratios, relay-defined NADP(H) responses, and unresolved NAD(P)H-associated contrast are not biologically interchangeable. The same biological question may be approached through sensor-accessible cofactor binding, a concentration-ratio sensor, a redox relay, accumulated hydride-transfer product, or label-free lifetime contrast, yet these outputs justify different conclusions. Accordingly, this section uses representative case studies rather than exhaustive disease coverage to ask which perturbations, orthogonal measurements, and controls connect defined NADPH-related optical endpoints to defensible metabolic claims. Table 6 consolidates supported interpretations and the highest-impact residual confounders across compartment-resolved physiology, cancer, infection, neurodegeneration, and renal or biofluid studies.

Table 6. Biological conclusion matrix for representative application domains.

Biological Question	Platform/Method	Directly Measured Quantity	Perturbation or Comparator	Orthogonal Support	Supported Conclusion	Key Confounder
Compartment-resolved metabolic physiology	iNap, NERNST, NAPstar, Apollo-NADP+, FLIM/phasor	Sensor-accessible NADPH/NADP+ response; concentration-ratio or relay-defined response; model-dependent lifetime contrast	Compartment targeting, in situ calibration, and pathway-specific perturbation	Extracted pools, isotope tracing, independent sensor, or complementary metabolic readout	Local cofactor or redox dynamics under the calibrated sensor/model conditions	Affinity, expression, buffering, relay coupling, pH, equilibrium, and lifetime-model assumptions
Cancer, hypoxia, and metabolic remodeling	KC8, Rh-DD-QL, compact cyanines, quinoline indicators	Accumulated NAD(P)H-responsive reaction signal	p53 status, hypoxia, histology, or tumor-model comparison	Histology, G6PD/pathway perturbation, animal or tissue comparison where reported	Platform-specific disease-associated optical contrast	Delivery, perfusion, attenuation, uptake, viability, and organelle state
Infection and inflammation	NAFP4; CyQ	Mitochondria-associated NAD(P)H-responsive signal; dual enzyme-responsive channels	Influenza infection or bacterial/non-bacterial inflammation models	Pathogen/inflammation classification and model perturbation	Context-specific imaging or multiplexed discrimination	Cell composition, oxygenation, ROS, bacterial burden, and channel cross-talk
Neurodegeneration and mitochondrial dysfunction	TQ1, NADH-R, two-photon reaction probes	Accumulated reaction signal, sometimes followed by product redistribution	Dopaminergic toxicity, mitochondrial dysfunction, or cholinergic impairment models	Cellular perturbation, intravital imaging, or independent metabolic readout where reported	Subcellular or tissue-level metabolic contrast	Membrane potential, organelle loss, morphology, product migration, and attenuation
Renal tissue and biofluids	Compact cyanines; CKD-pro	Tissue reaction contrast or matrix-dependent urine endpoint	Disease-group, pathology, or staging comparison	Recovery, clinical-marker comparison, and cohort analysis where reported	Discrimination under the stated analytical protocol	Urine pH, specific gravity, endogenous absorbers, medication, and renal-function covariates

7.1. Compartment-Resolved Metabolic Physiology

Protein-defined and label-free platforms offer particular value for resolving local metabolic dynamics rather than assigning an undifferentiated disease biomarker. Section 3 and Table 3 define their non-equivalent endpoints.

These outputs complement one another without becoming interchangeable. Even within the same compartment, changes in sensor occupancy, concentration ratio, relay output, and lifetime distribution may diverge in both direction and time scale. The supported conclusion should therefore specify both the exact endpoint and the operating range of the sensor or model.

Causal interpretation gains strength when a compartment-specific perturbation is paired with an independent measurement of extracted pool size, isotope-resolved flux, or an adjacent redox variable [17,81,82,83]. Such experiments help distinguish local adaptation from redistribution, sensor saturation, and broader changes in cell state [17,89].

7.2. Cancer, Hypoxia, and Metabolic Remodeling

Figure 16A shows the pH-dependent fluorescence response, Figure 16B compares relative fluorescence in normal and tumor-bearing groups, Figure 16C shows normoxic and hypoxic cellular fluorescence with quantification, and Figure 16D shows time-dependent photoacoustic intensity across experimental groups. Together, these panels relate analytical and biological controls to disease-associated contrast while preserving the distinction between accumulated reaction product and free NADPH. Cancer and hypoxia studies deployed KC8, Rh-DD-QL, compact cyanines, and quinoline-based indicators to test whether disease-associated metabolic states generated distinguishable optical contrast [55,56,61,75]. Related tumor-classification and therapeutic studies extended the same strategy to histological grading and multimodal treatment monitoring [96,104]. Under the reported conditions, the most defensible interpretation treated these signals as accumulated NAD(P)H-responsive reaction products rather than interchangeable measurements of free NADPH concentration [24,25,56,61]. Moreover, independent cancer-biology studies showed that glutathione and thioredoxin pathways could cooperate to sustain redox capacity; an optical response should therefore not be assigned to a single NADPH-producing route [105].

Figure 16. Analytical and biological controls used in cancer and hypoxia models. (A) pH-dependent fluorescence response. (B) Relative fluorescence in normal and tumor-bearing groups. (C) Cellular fluorescence under normoxic and hypoxic conditions with quantification. (D) Time-dependent photoacoustic intensity across experimental groups. In (A), colored spectra correspond to the pH values listed in the legend. In (B,D), H1–H3 and C1–C4 are the original experimental group labels from the cited studies. In (C), the white horizontal bar denotes the microscopy scale bar and the asterisk indicates a statistically significant difference reported in the source study. Error bars are reproduced as reported in the original studies. Reproduced with permission [55,56,61,75].

Associations with p53 status, hypoxia, tumor metabolism, histology, or tissue pathology provide useful proof-of-concept contrast [5,106,107]. G6PD perturbation, hypoxic exposure, histological comparison, and animal models strengthen that attribution [56,89,96,104]. Nevertheless, delivery, perfusion, attenuation, uptake, viability, and organelle state remain plausible alternative contributors [32,61,63,65]. Parallel adaptation of glycolytic and pentose-phosphate pathways can likewise alter cellular reducing capacity without being resolved by the imaging signal [108,109].

The evidence therefore supports a narrower conclusion than a general statement about tumor NADPH: these platforms detect model- and protocol-specific metabolic contrast consistent with altered reducing capacity [96,104,106,107]. Optical contrast alone, however, cannot identify the producing pathway or distinguish increased generation from decreased consumption, altered compartmentation, or probe delivery [5,108,109,110]. Any causal claim about NADPH concentration or flux consequently requires an independent pool or flux measurement and, ideally, a rescue that restores both metabolism and the optical response [81,82,83,89].

7.3. Infection, Inflammation, and Multiplexed Discrimination

In infection and inflammation models, NAFP4 tracked a mitochondria-associated response during influenza infection, whereas CyQ combined an NAD(P)H-responsive channel with a nitroreductase-responsive channel to distinguish bacterial from non-bacterial inflammatory settings. Because the two channels report different chemical events, they should not be collapsed into a single measure of immune-cell NADPH [50,51].

Collectively, infection and inflammation studies show how cofactor-associated optical contrast can add temporal or multiplexed information to disease models [7,111,112,113]. That added information, however, remains sensitive to cell composition, oxygenation, ROS production, mitochondrial state, substrate use, pathogen burden, and channel cross-talk [114,115,116,117].

Current evidence most strongly supports context-specific imaging and multiplexed discrimination [50,51]. Resolving NADPH flux, by contrast, requires cell-type-specific perturbations, independent redox measurements, and controls for pathogen burden and inflammatory composition because immune-cell recruitment changes mitochondrial abundance, oxidase activity, and substrate use [7,114,115,117]. Cell-resolved or lineage-restricted measurements consequently provide a more informative basis than bulk intensity for assigning a response to a defined immune compartment [114,115].

7.4. Neurodegeneration and Mitochondrial Dysfunction

Neurodegeneration studies must separate a probe’s chemical response from its cellular localization and from any time-dependent redistribution of the reduced product. NATP-3 provides a two-photon reaction-based signal, whereas TQ1 and NADH-R combine hydride-triggered fluorescence with distinct localization or redistribution behavior [33,53,54]. Although these formats have been applied to brain-cell, dopaminergic-toxicity, and intravital models, their outputs remain integrated reaction signals rather than direct measurements of free NADPH [24,25].

Across these studies, the reported optical readouts establish subcellular or tissue-level feasibility while revealing contrast associated with mitochondrial dysfunction, neurotoxicity, or altered neuronal metabolism [33,53,54]. Yet membrane-potential-dependent loading, product migration, and tissue attenuation can generate similar spatial changes [33,53,54]. Organelle loss and altered neuronal morphology add further disease-related confounding [118,119,120].

Mechanistic conclusions gain strength when optical changes are paired with independent metabolic, genetic, or biochemical validation and when localization is tracked over time [33,53,54]. Without those controls, the studies support disease-associated contrast and imaging feasibility more securely than any unique causal pathway of NADPH dysregulation [24,25,33,54].

Neural tissue presents intertwined temporal and cellular-composition challenges: neuronal activity, astrocyte support, mitochondrial transport, oxidative stress, and infiltrating immune cells affect reduced-cofactor signals on different time scales and in different directions [118,119,120]. A minimum validation set should therefore include membrane-potential and viability controls, quantitative time-resolved localization, cell-type-specific perturbation, and an orthogonal measurement of the NADP(H) pool or an adjacent redox variable [33,53,54]. Only with these experiments can one distinguish whether a signal precedes dysfunction, reflects compensation, or merely accompanies loss of viable tissue.

7.5. Renal Disease and Clinical Translation

Renal studies encompass analytically distinct settings. Compact cyanines and 6-quinolinium probes were applied to diseased kidney tissue, yielding local accumulated optical contrast, whereas CKD-pro underwent evaluation for urine screening and staging as a matrix-dependent biofluid assay. These outputs therefore cannot be collapsed into a single measure of renal NADPH [31,55,79].

Clinical discrimination and molecular specificity represent separate analytical achievements. A urine signal may classify renal disease without establishing molecular selectivity for NADPH because classification performance and NADH/NADPH discrimination address different analytical questions [24,25,31]. Likewise, tissue-probe studies can establish pathological contrast under reported model conditions without, by themselves, demonstrating clinical generalizability [55,79].

Clinical translation will require a locked analytical protocol—including standardized pre-analytical handling and reporting—rather than merely a larger cohort [31,84,85]. Prospective studies should therefore prespecify design and analysis and report both transparently, enabling reproducibility to be assessed across sites [90,91].

Taken together, the case studies expose a recurrent boundary between demonstrable optical contrast and defensible biochemical explanation: disease-associated contrast may establish biological association or discrimination without establishing a unique change in NADPH concentration or flux. The concluding section therefore returns to the framework as a whole, identifying the design, calibration, and reporting advances required to move NADPH-related optical measurements from descriptive contrast toward quantitatively interpretable and biologically actionable evidence.

8. Conclusions and Future Directions

Protein-defined platforms provide reversible, compartment-addressable readouts of binding-, relay-, ratio-, or assembly-defined variables [14,15,18,19]. Their interpretation, however, rests on the stated operating range and calibration rather than on a generic “NADPH sensor” label [28,46,47,49]. Broader analyses of biosensor engineering reinforce this point: affinity, dynamic range, reversibility, and cellular context jointly determine interpretability [76].

Reaction-based small molecules extend spectral and imaging flexibility across two-photon, NIR, ratiometric, and other long-wavelength formats [33,55,57,60]. Yet their common hydride-transfer chemistry remains shared by NADH and NADPH, producing a time-integrated reaction signal [23,24,25,26]. Unless matched mixed-cofactor experiments support narrower wording, NAD(P)H-responsive remains the appropriate classification [24,25,29,50].

Label-free autofluorescence, FLIM, and phasor analysis preserve native spatial context; nevertheless, they report endogenous intensity or binding-state metrics rather than universal absolute free-NADPH concentrations.

Viewed comparatively, these modalities are complementary rather than forming a simple hierarchy of analytical performance. Protein-defined sensors offer reversible, compartment-addressable measurements when affinity and calibration are controlled, but they require sensor expression or assembly and may perturb the measured pool. Reaction-based probes provide the greatest spectral and deployment flexibility, including NIR and two-photon imaging, but generally sacrifice reversibility and often NADH/NADPH discrimination because their signals integrate hydride-transfer chemistry over time. Label-free FLIM and phasor approaches avoid exogenous reporters and preserve native spatial context, yet their biochemical assignment remains model-dependent, whereas extraction and enzyme-defined assays provide stronger chemical definition at the cost of compartmental information. Method selection should therefore follow the biological question: compartment-resolved dynamics favor reversible protein sensors, flexible or deeper imaging favors reaction-based probes, native metabolic contrast favors label-free approaches, and recovered-pool quantification favors extraction or enzyme-defined assays. Consistent with Section 7, analytical performance and biological interpretability are not interchangeable. Across cancer and hypoxia, infection and inflammation, neurodegeneration, and renal applications, disease-associated optical contrast should therefore be interpreted at the level warranted by the measured endpoint rather than generalized automatically to free NADPH concentration or flux. Stronger biological claims require alignment of the endpoint with pathway-specific perturbation, sample-context controls, and orthogonal validation.

The next generation of methods should prioritize quantitative operating ranges and in situ calibration [16,46,47]. For reaction-based probes, matched NADH/NADPH kinetics, simultaneous mixed-cofactor competition, and product verification deserve particular emphasis [24,25,50]. Extracted and biological samples additionally require matrix-recovery studies and independent measurements of pool size or flux [81,82,83,84]. Collectively, these improvements will advance interpretability more than the addition of another uncalibrated emission channel [34,69,70].

Multimodal and multiplexed platforms will deliver real value only when their channels answer distinct questions. Structure-guided protein engineering, directed evolution, and small-molecule design can tune affinity, reversibility, pH sensitivity, and cofactor discrimination; meanwhile, integration with organoids, intravital microscopy, isotope tracing, single-cell metabolomics, and spatial methods can connect optical contrast to pathway-specific flux and cell identity.

Ultimately, progress will depend on interoperability among sensors, instruments, analysis pipelines, reference materials, and orthogonal assays. Shared calibration standards and reporting conventions would allow NADPH-related optical methods to move beyond descriptive contrast toward quantitative tools for mechanistic analysis, diagnosis, and treatment monitoring. These considerations were integrated into a unified methodological framework (Figure 17).

Figure 17. Integrative methodological framework for interpreting NADPH-related optical readouts. The reported biochemical variable or analytical endpoint is defined first; the platform is then mapped by analyte-defining event, photophysical transduction mechanism and observable optical readout, acquisition modality, and deployment context. Transduction and acquisition are shown together in the schematic for compactness but are treated as distinct descriptive dimensions in the text. Platform-specific validation limits biological interpretation to claims supported by the aligned endpoint, mechanism, sample context, and controls. In the hydride-transfer icon, H− denotes hydride.